title: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
abstract: Tamoxifen is used to prevent and treat estrogen-dependent breast cancer. It is described as a prodrug since most of its antiestrogen effects are exerted through its hydroxylated metabolites 4-OH-tamoxifen and endoxifen. In prior work, we correlated optimal plasma levels of these metabolites with certain genotypes of CYP2D6 and SULT1A2. This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4 Pro24Thr, UGT1A4 Leu48Val, UGT2B7 His268Tyr, UGT2B15 Asp85YTyr UGT2B15 Lys523Thr and UGT2B17del in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen. Patients were genotyped by real-time and conventional PCR-RFLP. The glucuronides 4-OH-tamoxifen-N-glucuronide, 4-OH-tamoxifen-O-glucuronide and endoxifen-O-glucuronide were isolated from blood plasma and quantified using a high-pressure liquid chromatography-tandem mass spectrometry system. Individuals who were homozygous for UGT1A448VAL showed significantly lower mean concentrations of both glucuronide metabolites compared to subjects genotyped as wt/wt plus wt/48Val (p=0.037 and p=0.031, respectively). Women homozygous for UGT2B7268Tyr also showed mean substrate/product ratios of 4-OH-tamoxifen/4-OH-tamoxifen-O-glucuronide and 4-OH-tamoxifen/4-OH-tamoxifen-N-glucuronide indicative of reduced glucuronidase activity compared to wt homozygotes or to heterozygotes for the polymorphism (p=0.005 and p=0.003, respectively). In contrast, UGT2B15 Lys523Thr and UGT2B17del were associated with possibly increased enzyme activity. Patients with at least one variant allele UGT2B15523Thr showed significantly higher 4-OH-tamoxifen-O-glucuronide and endoxifen-glucuronide levels (p=0.023 and p=0.025, respectively) indicating a variant gene-dose effect. Higher 4-OH-tamoxifen-N-glucuronide levels observed in UGT2B17del genotypes (p=0.042) could be attributed to a mechanism that compensates for the greater expression of other genes in UGT2B17 del/del individuals. Our observations suggest that patients carrying mutations UGT1A448Val, UGT2B7268Tyr or with wt genotypes for UGT2B17nodel and UGT2B15523Lys could be the best candidates for a good response to tamoxifen therapy in terms of eliciting effective plasma active tamoxifen metabolite levels. However, additional studies examining the effects of UGT genotype on overall patient response to TAM are needed to further examine the role of UGT polymorphisms in the therapeutic efficacy of TAM.
authors.affiliation: Department of Basic Biomedical Sciences, Faculty of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Romero-Lorca
authors.affiliation: Department of Basic Biomedical Sciences, Faculty of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.
authors.forename: Apolonia
authors.initials: A
authors.lastname: Novillo
authors.affiliation: Department of Basic Biomedical Sciences, Faculty of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Gaibar
authors.affiliation: School of Advanced Studies, Fundación Tejerina, Madrid, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Bandrés
authors.affiliation: Department of Basic Biomedical Sciences, Faculty of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Fernández-Santander
mesh_terms: D000483:Alleles; D001943:Breast Neoplasms / Q000097:blood / Q000201:enzymology* / Q000235:genetics*; D002851:Chromatography, High Pressure Liquid; D003710:Demography; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D005966:Glucuronidase / Q000235:genetics*; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D013058:Mass Spectrometry; D055442:Metabolome / Q000235:genetics; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens; D013629:Tamoxifen / Q000097:blood / Q000378:metabolism*
chemical_list: D015778:Minor Histocompatibility Antigens; C019787:bilirubin glucuronoside glucuronosyltransferase; D013629:Tamoxifen; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase; C472000:UDP-glucuronosyltransferase 2B15, human; C500513:UGT2B17 protein, human; D005966:Glucuronidase